{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:29:44Z","timestamp":1784903384187,"version":"3.55.0"},"reference-count":57,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Multiagent chemoimmunotherapy remains the standard of care treatment for Burkitt lymphoma leading to a cure in the majority of cases. However, frontline treatment regimens are associated with a significant risk of treatment related toxicity especially in elderly and immunocompromised patients. Additionally, prognosis remains dismal in refractory\/relapsed Burkitt lymphoma. Thus, novel therapies are required to not only improve outcomes in relapsed\/refractory Burkitt lymphoma but also minimize frontline treatment related toxicities. Recurrent genomic changes and signalling pathway alterations that have been implicated in the Burkitt lymphomagenesis include cell cycle dysregulation, cell proliferation, inhibition of apoptosis, epigenetic dysregulation and tonic B\u2010cell receptor\u2010phosphatidylinositol 3\u2010kinase (BCR\u2010PI3K) signalling. Here, we will discuss novel targeted therapy approaches using small molecule inhibitors that could pave the way to the future treatment landscape based on the understanding of recurrent genomic changes and signalling pathway alterations in the lymphomagenesis of adult Burkitt lymphoma.<\/jats:p>","DOI":"10.1111\/bjh.19425","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T03:54:41Z","timestamp":1712289281000},"page":"2165-2172","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah\u2010Yunes","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00857-w"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03288"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16425"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30126-5"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146036"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00650-10"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2010.55"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11378"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1747068"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016534"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14286"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22797"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014282"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2468"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2469"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.156885"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90682-X"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90434-0"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1891"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.9.1575"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1575"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1861409"},{"key":"e_1_2_11_24_1","first-page":"2951","article-title":"Omipalisib (GSK458), a dual an\u2010PI3K\/mTOR inhibitor, exhibits in\u00a0vitro and in\u00a0vivo activity in chemotherapy\u2010sensitive and\u2010resistant models of Burkitt lymphoma","volume":"132","author":"Ippolito T","year":"2018","journal-title":"Lymphoma"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25072"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1558.1558"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0848"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-721423"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.24.7824"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910170108"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.24.7837"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-871418"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204827"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03845"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-018-0008-7"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00500-y"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00235-2"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065493"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01020-07"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0605"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101483"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1561"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108190108"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3346"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30509-3"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117089"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1019"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914433107"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18215"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.12.009"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110448"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95864"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02450-3"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3438"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437624"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0511"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129052"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194691"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T10:09:23Z","timestamp":1754993363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/bjh.19425"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19425","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"2024-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}